
The drug developed by Moscow’s Gamaleya Institute and the Russian Direct Investment Fund may be approved for civilian use within three to seven days of registration by regulators, according to a person familiar with the process, who asked not to be identified because the information isn’t public.
from International-News-Economic Times https://ift.tt/3hPKJ0W
via
IFTTT
0 comments:
Post a Comment